Table 2.

Multivariate logistic regression model of variables associated with the administration of TEM-CAP rather than TEM alone, used to build the propensity score

	OR (95% CI)	p value
Hormonal syndrome (vs. absence)	0.45 (0.17–1.21)	0.12
Ki-67 index (each additional 1%)	1.05 (0.99–1.12)	0.09
Delay to initial diagnosis (each additional month)	0.99 (0.98–1.12)	0.16
Previous chemotherapy administration (vs. absence)	0.30 (0.12–0.76)	0.01
Previous somatostatin analog administration (vs. absence)	0.66 (0.25–1.71)	0.39

Bold type denotes significance. TEM, temozolomide; CAP, capecitabine.